Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | mIRT to support Direct-to-Patient (DtP) Clinical TrialBy: DDismart mIRT's Clinical Trial Supplies Management Technology Allows Pharmaceutical Companies to Continue Clinical Research Efforts Amidst the COVID-19 Pandemic in Accordance with FDA Guidelines DDi's mIRT offering sponsors the flexibility to ship drug directly from the site, depot and/or central pharmacy to the patient's home with its Direct to Subject module. Direct-to-Patient clinical trials are absolutely contactless and they are carried out within the patient's house preventing them from traveling to the investigator site. Amidst the COVID-19 pandemic, the importance of DtP clinical trial models are doubled to ensure patient safety and make accession of trial kits easier. In turn, it curbs the challenges of site capacity and disruption in the supply chain. mIRT's Direct to subject module supports all main models of Direct-to-Patient models that include Depot-to-Patient, Central-Pharmacy- Direct-to-Patient clinical trials aim at improving enrollment and make accession of trial sites easier for patients. COVID-19 might be the catalyst that moves the industry towards a DtP approach but its advantages stand clear. About DDi: DDi (Drug Development informatics) End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|